-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Evommune, Lowers Price Target to $25

Benzinga·11/13/2026 18:19:47
Listen to the news
Needham analyst Serge Belanger maintains Evommune (NYSE:EVMN) with a Buy and lowers the price target from $28 to $25.